These results suggest that HCC patients with high levels of CDK19 are more prone to having tumors that are more advanced in terms of tumor stage, tumor grade, metastasis and TP53 mutation status than those with low levels of CDK19 expression. Here, TP53 is linked to hepatocellular carcinoma.